Comparison · NCT03220958-c8447d2f
Metoclopramide vs Placebo: Sustained Headache Relief
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Metoclopramide vs Placebo: Sustained Headache Relief. Trial comparisons, record NCT03220958-c8447d2f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03220958-c8447d2f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.308 | 0.216 | 0.417 | wilson | |
| Risk in group 2 | 0.237 | 0.155 | 0.344 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0709 | -0.0697 | 0.207 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.3 | 0.77 | 2.19 | log | |
| Odds ratio, group 1 over group 2 | 1.43 | 0.701 | 2.93 | log | |
| Number needed to treat, for one more participant with the outcome on Metoclopramide than on Placebo | 14.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Metoclopramide | Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip~Metoclopramide: Metoclopramide 20mg~Diphenhydramine: Diphenhydramine 25mg~Normal saline: 100ml normal saline | 24 | 78 | OG000 |
| Group 2 | Placebo | Normal saline, administered as an intravenous drip~Normal saline: 100ml normal saline | 18 | 76 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Sustained Headache Relief
- Description
- Achieving a headache intensity of mild or none in the ED without use of rescue medication and maintaining a level of mild or none. Participants rate their headache as none, mild, moderate, or severe
- Time frame
- 48 hours after medication administration
- Population
Source ClinicalTrials.gov
Trial
- Title
- Metoclopramide for Post Traumatic Headache
- NCT number
- NCT03220958
- Phases
- PHASE3
- Conditions
- Post-Traumatic Headache
- Interventions
- Metoclopramide, Diphenhydramine, Normal saline
- Lead sponsor
- Montefiore Medical Center
- Results first posted
- 2021-11-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03220958?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03220958-c8447d2f